VivoSim Labs (FRA:4OR) Cyclically Adjusted FCF per Share: €-76.98 (As of Dec. 2025)


FRA:4OR VivoSim Labs Inc FRA:4OR
39 GF Score
Price €3.49
GF Value €8.71
! 4 Warning Signs
View Full Analysis

What is VivoSim Labs Cyclically Adjusted FCF per Share?

VivoSim Labs FRA:4OR 39 Cyclically Adjusted FCF per Share is €-76.98 as of Dec. 2025. GuruFocus rates FRA:4OR with a GF Score™ of 39/100 and a GF Value™ of €8.71. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

VivoSim Labs's adjusted free cash flow per share for the three months ended in Dec. 2025 was €-0.743. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-76.98 for the trailing ten years ended in Dec. 2025.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 6.30% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of VivoSim Labs was 6.30% per year. The lowest was -2.60% per year. And the median was 0.70% per year.

As of today (2026-06-30), VivoSim Labs's current stock price is €3.492. VivoSim Labs's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2025 was €-76.98. VivoSim Labs's Cyclically Adjusted Price-to-FCF of today is .


VivoSim Labs  (FRA:4OR) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


VivoSim Labs Cyclically Adjusted FCF per Share Related Terms


VivoSim Labs Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for VivoSim Labs's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VivoSim Labs Cyclically Adjusted FCF per Share Chart

VivoSim Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -46.46 -50.62 -53.87 -49.14 -74.16

VivoSim Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.74 -74.16 -107.47 -50.74 -76.98

FRA:4OR vs SLXN, CDT, CLDI: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, VivoSim Labs's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VivoSim Labs Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's Cyclically Adjusted Price-to-FCF falls into.


FRA:4OR
39GF Score
VivoSim Labs Inc FRA:4OR
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VivoSim Labs Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, VivoSim Labs's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-0.743/324.0540*324.0540
=-0.743

Current CPI (Dec. 2025) = 324.0540.

VivoSim Labs Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201603 -18.952 238.132 -25.790
201606 -19.771 241.018 -26.583
201609 -15.634 241.428 -20.985
201612 -17.204 241.432 -23.091
201703 -16.198 243.801 -21.530
201706 -21.911 244.955 -28.986
201709 -11.731 246.819 -15.402
201712 -12.246 246.524 -16.097
201803 -10.111 249.554 -13.129
201806 -12.955 251.989 -16.660
201809 -7.802 252.439 -10.015
201812 -7.178 251.233 -9.259
201903 -9.022 254.202 -11.501
201906 -9.928 256.143 -12.560
201909 -8.621 256.759 -10.881
201912 -0.965 256.974 -1.217
202003 -5.338 258.115 -6.702
202006 -4.195 257.797 -5.273
202009 -11.095 260.280 -13.814
202012 -2.143 260.474 -2.666
202103 -2.784 264.877 -3.406
202106 -1.840 271.696 -2.195
202109 -2.548 274.310 -3.010
202112 -4.259 278.802 -4.950
202203 -1.996 287.504 -2.250
202206 -3.242 296.311 -3.546
202209 -3.249 296.808 -3.547
202212 -4.012 296.797 -4.380
202303 -6.298 301.836 -6.762
202306 -6.771 305.109 -7.191
202309 -4.094 307.789 -4.310
202312 -4.250 306.746 -4.490
202403 -2.939 312.332 -3.049
202406 -2.268 314.175 -2.339
202409 -1.587 315.301 -1.631
202412 -1.143 315.605 -1.174
202503 -1.157 319.799 -1.172
202506 -1.364 322.561 -1.370
202509 -0.778 324.800 -0.776
202512 -0.743 324.054 -0.743

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-76.98 mean?
VivoSim Labs (FRA:4OR) has a Cyclically Adjusted FCF per Share of €-76.98 as of Dec. 2025. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on VivoSim Labs and its competitors.
Is VivoSim Labs' Cyclically Adjusted FCF per Share too high?
VivoSim Labs' current Cyclically Adjusted FCF per Share is €-76.98. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Cyclically Adjusted FCF per Share compare to SLXN and CDT?
VivoSim Labs' Cyclically Adjusted FCF per Share of €-76.98 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current Cyclically Adjusted FCF per Share is €-76.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Cyclically Adjusted FCF per Share of €-76.98. The stock's GF Value™ is €8.71, compared to a current price of €3.49 — trading 59.9% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-76.98. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Cyclically Adjusted FCF per Share is €-76.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is VivoSim Labs (FRA:4OR) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of €3.49 is trading 59.9% below its estimated GF Value™ of €8.71.

Key valuation signals for FRA:4OR:

  • Cyclically Adjusted FCF per Share: €-76.98
  • GF Value™: €8.71 vs. price of €3.49 (59.9% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


VivoSim Labs Business Description

Other Exchanges VIVS:USA
Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score

Get the complete analysis for FRA:4OR

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.49
Price
€8.71
GF Value